Ursodeoxycholic acid (UDCA) and obeticholic acid are the only two primary biliary cholangitis drugs that the Food and Drug Administration (FDA) has approved for treating primary biliary cholangitis (OCALIVA). UDCA is still the go-to first-line treatment for primary biliary cholangitis despite the introduction of promising second-line therapies for PBC patients who are UDCA-intolerant or UDCA-naive. The UDCA's good long-term efficacy and safety profile and affordable primary biliary cholangitis treatment are the main reasons for the sustained trust. By enhancing hepatobiliary secretory function and lowering bile toxicity, UDCA has anti-cholestatic effects. Obeticholic acid (OCA), OCALIVA was the second medication to be approved for use in patients who had an inadequate response to UDCA or were intolerant as well as those who were UDCA-naive. For 40 to 80% of people with primary biliary cholangitis, fatigue is the most often reported symptom of their condition. Fatigue has crippling physical repercussions that affect patients' capacity to accomplish everyday tasks, and it also negatively affects their mental health, social life, family life, sexual life, and work performance. https://www.delveinsight.com/report-store/primary-biliary-cholangitis-pipeline-insight?utm_source=blog&utm_medium=promotion&utm_campaign=supr